ANAB

ANAB

USD

AnaptysBio Inc. Common Stock

$34.740-1.230 (-3.420%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$35.970

Máximo

$36.500

Mínimo

$34.595

Volume

0.76M

Fundamentos da empresa

Capitalização de mercado

971.8M

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

0.52M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $12.21Atual $34.740Máximo $38.385

Notícias relacionadas

GlobeNewswire

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./Dec.

Ver mais
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire

Anaptys Announces Participation in November Investor Conferences

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president

Ver mais
Anaptys Announces Participation in November Investor Conferences
Analyst Upgrades

Stifel Maintains Buy on AnaptysBio, Raises Price Target to $80

Stifel analyst Alex Thompson maintains AnaptysBio with a Buy and raises the price target from $55 to $80.

Ver mais
Stifel Maintains Buy on AnaptysBio, Raises Price Target to $80
GlobeNewswire

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

New data reinforce rosnilimab's efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including

Ver mais
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation